Auxilium Pharmaceuticals was founded in 1999 to develop and market pharmaceutical products that focus on urology and sexual health and has since expanded to address various other medical conditions. The company’s current product pipeline includes Xiaflex, a collagenase enzyme for intralesional injection for the treatment of Dupuytren’s contracture, Peyronie's disease, and Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium has secured exclusive options to license global commercial rights for all future (non-topical formulation) indications for Xiaflex. Auxilium has also developed a new oral transmucosal drug-delivery system based on technology licensed from Formulation Technologies, Inc.
CSRHub includes data on Carbon Disclosure Project, CSR, Global Reporting Initiative, Sustainability, Roboinvesting, and socially responsible investing.